www.drugdevelopment-technology.com
News, views and contacts from the global Drugdevelopment industry
23 May 2017
WEEKLY UPDATE
Digital Magazine
Latest Companies

Malvern Instruments - Biopharmaceutical and Drug Development

SYSTAG Systems Technik - Automation Systems for Small-Molecule Drug and API Development

Softigel - Contract Development Services and Drug Delivery Systems

Pfanstiehl - Injectable and HPLE Carbohydrates for Protein Stabilisation and Optimisation

Biovian - Contract Manufacturing Of Biopharmaceuticals

Press Releases

Gamlen Instruments Announces New Company Name
Gamlen Tableting has announced it is changing its trading name from 'Gamlen Tableting' to 'Gamlen Instruments' to acknowledge the company's established global presence as a leader in benchtop powder compaction instrumentation.

Malvern to Host Webinar on Using Multi-Setection size-exclusion chromatography to Evaluate Biosimilarity
Malvern has announced it will be hosting a new webinar presenting size-exclusion chromatography (SEC) data and discussing the impact of different formulations and external stress conditions on Monoclonal antibodies and biosimilar molecules.

Malvern to Host New Webinar on Difference Between Rheometers and Viscometers
Malvern has announced it will host a new webinar discussing the difference between rheometers and viscometer to help viewers decide which of the two is most suitable for their application.

Pharmatest to Host Seven Presentations at AACR in Washington, US
Pharmatest Services has announced it will attend the annual meeting of American Association for Cancer Research (AACR) in Washington, US.

Shin-Etsu Purchase Gamlen D Series for Formulation Studies
Provider of a wide range of cellulose ether excipients Shin-Etsu PFMD has purchased a Gamlen D series powder compaction analyser for a laboratory application in Wiesbaden, Germany.

White Papers

Analysing Polysaccharides Using OMNISEC
Malvern notes how moving to multi-detector gel permeation chromatography (GPC) or size-exclusion chromatography (SEC) can provide greater insight than conventional measurements....

Application: Operating Reactor Systems for Process Research and Development
In this case study, three reactor systems (FlexyCUBE 70ml, FlexyPAT 2l, and ChemTeacktor 25l) are operated on the same PC using application software...

Paradigm Shift Regarding API and Formulation Components
This whitepaper will provide an introduction to high-purity carbohydrates often used for applications such as stabilisation, modulation, and cryopreservation, comparing the old paradigm...

Optimising Development Resources for Efficient Product Development
Development departments suffer from a shortage of resources and are often overburdened with administration...

Top 10 Factors When Choosing a DLS Instrument
The physical components and features of a dynamic light scattering (DLS) instrument, along with the instrument's technical specifications, are important when purchasing a new...

Features

April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial
The National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) began the Phase II/IIb clinical trial of a Zika vaccine, and Boehringer Ingelheim began patient enrolment in the Phase III PF-ILD trial of nintedanib to treat various progressive fibrosing lung diseases. Drug development-technology.com wraps up the key headlines from April.

March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis
Cancer Research UK invested £10m in the PRECISION Panc project, including a network of clinical trials for the treatment of pancreatic cancer, and Novartis reported positive results from the extension A2302E1 trial of Cosentyx to modify the course of psoriasis. Drugdevelopment-technology.com wraps up the key headlines from March.

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial
Merck reported positive results from the Phase III trial of its non-nucleoside reverse transcriptase inhibitor (NNRTI) doravirine (MK-1439) for the treatment of patients with HIV-1 infection, and NIH's NIAID initiated a Phase I trial of vaccine AGS-v to prevent mosquito-transmitted diseases. Drugdevelopment-technology.com wraps up the key headlines from February.

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk
TG Therapeutics began its Phase II investigator initiated trial of TGR-1202 in combination with ibrutinib to treat Diffuse Large B-cell Lymphoma (DLBCL), and a study suggested that antidepressant usage increases the risk of hip fracture. Drugdevelopment-technology.com wraps-up the key headlines from January.

2016: The year's biggest Drug Development Technology stories
NIAID began a new HIV vaccine study in South Africa and Eli Lilly’s Phase III trial of Alzheimer disease drug failed. Drugdevelopment-technology wraps-up the key headlines from 2016.

Projects

Dinutuximab beta for the Treatment of Neuroblastoma
Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above.

Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC)
Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC).

Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)
Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC).

Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis
Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytosis (SM) indications.

Follow Us:   Facebook Facebook    Twitter Twitter   
Click here to unsubscribe from the newsletter | Privacy Policy
You are receiving this email because you are either a valued subscriber to Drug Development Technology or have signed up via a partner web site. Your email address has not been, and will not be, given to third parties.

www.drugdevelopment-technology.com is a product of Kable. Copyright 2017 Kable, a trading division of Kable Intelligence Limited.